Causes of Body Maladaptive Somatic Changes During Aging

• Decreased concentrations of some hormones, especially growth hormone (hGH), insulin-like growth factor-1 (IGF-1) and secondarily, testosterone (Test).

• Reduced neural conductivity between the brain and neuroendocrine system.

• Increased pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 as well as leptin.

• Decreased ability to synthesize protein.

• Increased oxidative damage due to reduced antioxidant enzymes in skeletal muscle

​

Through the combined actions of complementary ingredients working at various loci throughout the body, the multiple causes of maladaptive changes in body composition that progress during aging, especially muscle loss and sarcopenia are slowed by SarcotropinSL®

​

Clinical Trial Data Summary 

• Insulin-like growth factor-1 (IGF-1) increased 16.35% from baseline to 90 days of treatment.  No significant changes in IGF-1 levels occurred in subjects receiving placebo.

• Body Mass Index (BMI) and total body water did not change significantly in either treatment or placebo groups during the course of study.

• Total body fat decreased  5.57%  and 9.14% after 45 and 90 of treatment, respectively.

• Visceral fat was reduced by 10.3% and 14.27% after 45 and 90 days of treatment, respectively.

• There were no changes in total or visceral body fat within the placebo group.

• Lean body mass increased 5.37% after 90 days treatment compared to placebo which was not associated with change in muscle mass.

 

Liver/Muscle/Bone Vitamin D3 (Cholecalciferol)

Vitamin D3 increases circulating IGF1 in adults. As a result, a better vitamin D status may ease the achievement of normal IGF1 values in GHD.Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency.  Ameri P, Giusti A, Boschetti M et al.  Eur J Endocrinol 169(6):767-772, 2013.doi: 10.1530/EJE-13-0510.Print 2013 Dec.

Treatment with active vitamin D was associated with greater muscle size and strength. The Relationship between Vitamin D and Muscle Size and Strength in Patients on Hemodialysis.  Gordon P, Sakkas, G, Doyle J, et al. Ren Nutr. 17(6): 397-405, doi: 10.1053/j.jrn.2007.06.001

Vitamin D supplementation restores muscle size and strength associated with hypovitaminosis D.Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement.Glerup H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, et al. Calcif Tissue Int. 2000 Jun; 66(6):419-24.

SarcotropinSL® Safety

During Clinical Testing, no significant changes in biochemical or hematological parameters were noted.  There were neither unexpected adverse events nor serious adverse events reported during the course of the 90 day study.

PreClinical testing involved acute, repeat dosing and genotoxicity animal studies.  The results of all tests were negative.  A human, No Observable Adverse Event Level (NOAEL) based upon rat data was 8 mg/kg, which is well above commonly used human doses of 0.05 to 0.1 mg/kg.  Thus, these findings and lack of toxicity reports in the literature support the view that GHRP-2 is safe for human consumption in treating sarcopenia. 

Contraindications

Although there are no clinical reports or published evidence of risk from taking the product, SarcotropinSL® is not recommended for use in those with following conditions:

• Chronic gastrointestinal distress associated with abdominal pain and/or diarrhea

• Pancreatitis

• Active malignancies

• Type 2 diabetes (?)